DOVE Study: Determining Effects of Platelet Inhibition on Vaso-occlusive Events
The DOVE study will assess the efficacy of prasugrel compared to placebo in pediatric patients with sickle cell disease.
The DOVE study will assess the efficacy of prasugrel compared to placebo in pediatric patients with sickle cell disease.
The EPIC study aims to demonstrate the efficacy of MST-188 in reducing the duration of vaso-occlusive crisis in children with SCD and compare rates of re-hospitalization rate and acute chest syndrome between the treatment arms.
Study to show the efficacy and safety of Ferriprox for the treatment of transfusional iron overload in patients with sickle cell disease or other anemias.
The study "Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children" is a randomized placebo-controlled trial of HU to reduce the CNS complications of sickle cell disease.
The study "Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children" is a randomized placebo-controlled trial of HU to reduce the CNS complications of sickle cell disease.
"In Vitro Studies of Sickle Cell Disease Drugs" aim to find new drugs for the treatment of sickle cell disease.
Alan Flake, MD, director of CHOP’s Center for Fetal Research, is on the verge of a potential cure for sickle cell disease using prenatal stem cell transplants.
The study "Red Blood Cell Genotyping in Sickle Cell Disease" will determine the prevalence of altered RH genes in SCD patients and more.
Hematopoietic stem cell transplantation in utero (IUHSCTx) is a promising approach for the treatment of a variety of hematologic disorders, including sickle cell disease, CHOP researchers say.
TWiTCH is a study comparing erythrocyte transfusions withhydroxyurea for the maintenance of lowered TCD velocities in children with sickle cell anemia and abnormal pre-treatment TCD velocities.